Quratis Inc is a Korea-based company primarily engaged in the manufacture and sale of biopharmaceuticals. The Company is engaged in the manufacture and sale of vaccine, peptide nucleic acid complex. The Company is also engaged in the provision of Cell Penetrating Peptide (CPP) platform services. In addition, the Company is engaged in the development and research of vaccines, such as tuberculosis vaccines for adults and adolescents, and COVID-19 vaccines.

Employees

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
26-10-29	₩3,515.00	+0.57%	18,399
26-10-28	₩3,495.00	+2.79%	16,465
26-10-27	₩3,400.00	+5.43%	18,769
26-10-26	₩3,225.00	-3.15%	9,631
26-10-23	₩3,330.00	-0.60%	17,848

End-of-day quote Korea S.E.

More quotes

End-of-day quote Korea S.E. 2026-10-29			5-day change	1st Jan Change
3,515.00 ^KRW	+0.57%		+4.93%	-69.96%

03-15	Quratis Inc. announced that it has received KRW 10.000000167 billion in funding from Inventage Lab, Inc.	CI
03-05	Quratis Inc. announced that it expects to receive KRW 10.000000167 billion in funding from Inventage Lab, Inc.	CI

Market Cap	41.23B 30.74M 27.54M 25.4M 22.99M 42.99M 2.93B 43.68M 303M 121M 1.53B 115M 113M 4.85B	P/E 2024	-9.06x	P/E 2025	-28.4x
Enterprise Value	41.38B 30.85M 27.64M 25.5M 23.07M 43.14M 2.94B 43.84M 304M 121M 1.54B 116M 113M 4.87B	EV / Sales 2024	136x	EV / Sales 2025	43.3x
Free-Float	37.62%	Yield 2024 *	-	Yield 2025	-

03-15	Quratis Inc. announced that it has received KRW 10.000000167 billion in funding from Inventage Lab, Inc.	CI
03-05	Quratis Inc. announced that it expects to receive KRW 10.000000167 billion in funding from Inventage Lab, Inc.	CI
02-25	Inventage Lab, Inc. agreed to acquire an additional 12.79% stake in Quratis Inc. for KRW 13.5 billion.	CI
12-23	Quratis wins contract amount of 1 billion won	RE
25-08-21	Access to Advanced Health Institute Partners with Quratis to Strengthen Global Vaccine Manufacturing and Accelerate Access to Lifesaving Vaccines	CI
25-06-19	Quratis To Invest 7 Billion Won In New Facility	RE
25-03-11	Quratis Inc. announced that it has received KRW 10.0329 billion in funding from Inventage Lab, Inc.	CI
25-02-20	Quratis Inc. announced that it has received KRW 15 billion in funding from Inventage Lab, Inc.	CI
24-11-24	Quratis Inc. announced that it expects to receive KRW 6.4993 billion in funding from Inventage Lab, Inc.	CI
24-11-14	Quratis Inc. announced that it has received KRW 10.4648 billion in funding from LINFRA Corp	CI
24-09-11	Quratis Inc. announced that it expects to receive KRW 10.4648 billion in funding from LINFRA Corp	CI
23-11-29	Quratis Inc. announced that it has received KRW 7.99999791 billion in funding from LINFRA Corp	CI
23-09-24	Quratis Inc. announced that it expects to receive KRW 7.99999791 billion in funding	CI

1 day	+0.57%
1 week	+4.93%
Current month	-5.89%
1 month	-8.82%
3 months	+84.81%
6 months	-54.05%
Current year	-69.96%

Quratis Inc. Stock

Stocks

A348080

KR7348080003

Pharmaceuticals

Valuation: Quratis Inc.

Chart: Quratis Inc.

Latest news: Quratis Inc.

Press Releases: Quratis Inc.

Quotes and Performance

Price Extremes

Managers and Directors: Quratis Inc.

Latest insider transactions

Other Pharmaceuticals

Financials

Company Profile

Quotes

1 week	3,100	3,550
1 month	3,075	4,250
Current year	1,765	13,050
1 year	1,765	13,365
3 years	1,765	27,810
5 years	1,765	60,210
10 years	1,765	60,210

Manager	Title	Age	Since
Seong Kim CEO	Chief Executive Officer	52	2024-12-15
Chi-Yeol Kim AUD	Comptroller/Controller/Auditor	48	2025-04-06

Director	Title	Age	Since
Dong-Hun Kim CHM	Chairman	56	2025-02-19
Hyeong-Gi Choi BRD	Director/Board Member	39	2025-02-19
Taek-Dong Kim BRD	Director/Board Member	63	2025-02-19

Date	Insider	Type	Quantity	% Market Cap.
5/7/25	Ki-Young Yang	Others	80,000	0.1380%
5/9/24	Woo Ryu Sung	Others	41,946	0.0995%
4/2/24	Sang-Rae Cho	Others	118,333	0.2807%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
QURATIS INC.	+0.57%	+4.93%	-57.08%	-87.74%	30.49M
ELI LILLY AND COMPANY	+6.63%	+5.13%	+68.86%	+145.20%	1,148B
JOHNSON & JOHNSON	+1.53%	+2.84%	+47.48%	+89.01%	652B
ABBVIE INC.	+1.68%	+1.96%	+29.16%	+109.31%	505B
ROCHE HOLDING AG	+0.73%	+2.45%	+54.26%	+68.96%	384B
MERCK & CO., INC.	+3.83%	-0.62%	+69.01%	+42.32%	348B
NOVARTIS AG	+2.38%	+2.65%	+34.31%	+57.95%	294B
ASTRAZENECA PLC	+2.26%	+0.55%	+3.92%	+28.92%	264B
AMGEN INC.	+1.97%	+3.01%	+57.91%	+76.14%	244B
GILEAD SCIENCES, INC.	+4.03%	+5.36%	+39.76%	+116.14%	197B
Average	+2.16%	+1.80%	+34.76%	+64.62%	403.72B
Weighted average by Cap.	+2.25%	+1.50%	+50.22%	+95.97%

	2024	2025
Net sales	374M 279K 250K 230K 208K 390K 26.54M 396K 2.75M 1.1M 13.89M 1.05M 1.02M 44M	2.46B 1.83M 1.64M 1.51M 1.37M 2.56M 174M 2.6M 18.06M 7.21M 91.31M 6.88M 6.73M 289M
Net income	-26.27B -19.59M -17.54M -16.19M -14.65M -27.39M -1.87B -27.83M -193M -77.04M -976M -73.51M -71.95M -3.09B	-29.67B -22.13M -19.82M -18.29M -16.55M -30.94M -2.11B -31.44M -218M -87.03M -1.1B -83.04M -81.28M -3.49B
Net Debt	16.3B 12.15M 10.89M 10.04M 9.09M 17M 1.16B 17.27M 120M 47.8M 606M 45.61M 44.64M 1.92B	149M 111K 99.59K 91.87K 83.14K 155K 10.59M 158K 1.1M 437K 5.54M 417K 408K 17.55M